Characteristics associated with cystic fibrosis-related pulmonary exacerbation treatment location

Shteinberg, 2021, Cystic fibrosis, Lancet, 397, 2195, 10.1016/S0140-6736(20)32542-3 Thornton, 2004, Long term clinical outcome of home and hospital intravenous antibiotic treatment in adults with cystic fibrosis, Thorax, 59, 242, 10.1136/thx.2003.005876 Schechter, 2018, Treatment setting and outcomes of cystic fibrosis pulmonary exacerbations, Ann Am Thorac Soc, 15, 225, 10.1513/AnnalsATS.201702-111OC Sanders, 2022, Association of site of treatment with clinical outcomes following intravenous antimicrobial treatment of a pulmonary exacerbation, J Cyst Fibros, 21, 574, 10.1016/j.jcf.2021.11.009 Heltshe, 2018, Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): a trial to compare intravenous antibiotic treatment durations in CF, Contemp Clin Trials, 64, 35, 10.1016/j.cct.2017.11.012 Goss, 2021, A randomized trial of antimicrobial duration for cystic fibrosis pulmonary exacerbation treatment, Am J Respir Crit Care Med, 204, 1295, 10.1164/rccm.202102-0461OC Knapp, 2016, The cystic fibrosis foundation patient registry. Design and methods of a national observational disease registry, Ann Am Thorac Soc., 13, 1173, 10.1513/AnnalsATS.201511-781OC United States Department of Agriculture. 2010 Rural-Urban Commuting Area (RUCA) Codes Documentation 2019. Accessed May 1, 2023 https://www.ers.usda.gov/data-products/rural-urban-commuting-area-codes.aspx. Sterne, 2009, Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls, BMJ, 338, b2393, 10.1136/bmj.b2393 Mackinnon, 2010, The use and reporting of multiple imputation in medical research - a review, J Intern Med, 268, 586, 10.1111/j.1365-2796.2010.02274.x Musumeci, 2020